ArticleOne health (Amsterdam, Netherlands)2023
Determining the acceptability of a novel One Health vaccine for Rift Valley Fever prior to phase II/III clinical trials in Uganda.
Article in One health (Amsterdam, Netherlands), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 5 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several vaccine candidates for Rift Valley Fever (RVF) are in development for use in humans. A promising candidate, ChAdOx1 RVF vaccine, has been developed for use in both humans and animals, and has undergone field trials in livestock in Kenya. We conducted a qualitative study to explore the acceptability of this novel One Health vaccine for Rift Valley Fever prior to phase II/III trials, in two rural Ugandan cohorts between January to June 2020. Data was obtained from 96 semi-structured interviews at Bwindi Impenetrable National Park (BINP) and Kyamulibwa, Kalungu District, in Southern Uganda. The study found that 42% of those interviewed were willing to receive a vaccine that was the same for both humans and animals. 45% of those interviewed said that they would not be willing to receive a One Health vaccine and a further 13% were unsure whether or not they would be happy to receive such a vaccine. Semi-structured interviews were conducted to explore their reasons for and against the acceptability of a novel One Health vaccine to highlight potential barriers to deployment once a vaccine candidate for RVF becomes available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.